As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...
A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...
Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...
Dementia drivers license loophole sparks safety concerns in South Korea Koreas lack of legal measures puts dementia patients ...
For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...
Millions of people with overactive bladder syndrome are prescribed daily anticholinergics. But research has linked these ...
Family urges action as Korean driver with dementia causes fatal crash Seoul lacks regulations on halting driving for dementia ...
A study from the Keck School of Medicine of USC has tested a biomarker linked to vascular dementia across four separate ...
Summary: A new study has identified a biomarker, DTI-ALPS, which connects glymphatic system dysfunction to vascular dementia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback